Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
BluGlass Limited is an Australian semiconductor technology company developing low-temperature remote plasma chemical vapor deposition (RPCVD) technology for manufacturing gallium nitride (GaN) LEDs and power electronics. The company operates as a pre-commercial R&D entity with minimal revenue, focused on licensing its proprietary manufacturing process to semiconductor manufacturers. The stock trades on extreme technology risk with binary outcomes dependent on commercial adoption of its RPCVD platform.
BluGlass aims to monetize its low-temperature RPCVD technology through licensing agreements with LED and power semiconductor manufacturers. The technology promises lower manufacturing costs and improved device performance compared to conventional metal-organic chemical vapor deposition (MOCVD). With 41.9% gross margin on minimal revenue, the company likely generates income from small-scale R&D contracts while burning cash to develop commercial-scale processes. The business model requires securing major licensing partners to achieve profitability, with potential for high-margin royalty streams if technology gains adoption. Current operating margin of -167.5% reflects pre-revenue development stage with ongoing R&D and administrative expenses.
Announcements of commercial licensing agreements or joint development partnerships with LED/power semiconductor manufacturers
Technical milestones demonstrating RPCVD performance advantages (efficiency improvements, cost reductions vs MOCVD)
Capital raising announcements and dilution events given negative cash flow and $1.95 current ratio
Broader GaN semiconductor market adoption trends for power electronics and RF applications
Competitive technology developments in low-temperature deposition methods
Technology adoption risk: RPCVD may fail to achieve cost or performance advantages sufficient to displace entrenched MOCVD processes in commercial manufacturing
Capital intensity of semiconductor industry: Major manufacturers may be unwilling to retool existing MOCVD infrastructure despite potential RPCVD benefits
Competitive technology development: Alternative low-temperature deposition methods or MOCVD improvements could obsolete BluGlass's technology before commercialization
Regulatory and IP protection: Patent challenges or inability to defend proprietary processes in key manufacturing jurisdictions (Asia)
Competition from established semiconductor equipment manufacturers (Applied Materials, Lam Research, ASML) with vastly superior resources and customer relationships
Risk that LED and power semiconductor manufacturers develop in-house low-temperature processes, bypassing licensing model
Geographic concentration risk: Most GaN manufacturing capacity is in Asia (Taiwan, China, Japan), requiring partnerships in regions with different IP protection standards
Going concern risk: With negative $0.0B operating cash flow and minimal revenue, the company faces existential funding risk if unable to raise capital
Dilution risk: Current ratio of 1.95 suggests limited cash runway, likely requiring equity raises in 2026 that will significantly dilute existing shareholders
Negative equity risk: ROE of -102.2% indicates accumulated deficits approaching shareholder equity, limiting balance sheet capacity for additional losses
Illiquidity: $0.1B market cap and -96.8% one-year return indicate extremely thin trading and high execution risk for institutional positions
moderate - As a pre-revenue technology company, BluGlass is somewhat insulated from near-term economic cycles. However, capital availability for speculative technology investments tightens during recessions, affecting fundraising ability. End-market demand for GaN semiconductors (EVs, 5G infrastructure, data centers) has cyclical exposure, influencing potential partners' willingness to invest in new manufacturing technologies. Industrial production trends affect semiconductor capex cycles.
High sensitivity to interest rates through multiple channels. Rising rates compress valuation multiples for pre-revenue growth companies, particularly those trading at 4.4x sales with negative cash flow. Higher rates increase discount rates applied to distant future cash flows, severely impacting NPV of speculative technology bets. Additionally, elevated rates reduce risk appetite for early-stage technology investments and make equity capital raises more dilutive. The company's ability to fund operations through 2026-2027 depends on access to growth capital, which becomes scarce in high-rate environments.
Minimal direct credit exposure with 0.61 debt-to-equity ratio, but significant indirect exposure through equity capital markets. The company requires ongoing equity financing to fund operations given negative free cash flow. Credit market stress reduces institutional appetite for speculative technology stocks and increases cost of capital for small-cap growth companies. Venture capital and growth equity availability contracts during credit tightening, threatening the company's ability to bridge to commercialization.
growth - Extremely speculative, binary-outcome technology bet attracting venture-style equity investors willing to accept total loss for potential 10-50x return if RPCVD achieves commercial adoption. The -96.8% one-year return, negative cash flow, and pre-revenue status make this unsuitable for value, income, or risk-averse growth investors. Typical holders would be Australian retail speculators, early-stage technology funds, and momentum traders on partnership announcements. Institutional ownership likely minimal given $0.1B market cap and liquidity constraints.
high - Extreme volatility driven by binary news flow (partnership announcements, capital raises, technology milestones). The 0.0% three-month and six-month returns alongside -96.8% one-year return suggest periods of complete illiquidity punctuated by sharp moves on news. Pre-revenue companies with existential funding risk exhibit beta well above 2.0 to broader markets, with idiosyncratic volatility dominating. Bid-ask spreads likely wide given thin float.
